Lilly points to long-lasting weight loss with orforglipron
Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
Newsletters and Deep Dive digital magazine
Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
The call lasted ten minutes. My manager was apologetic. HR was professional.
LIB Therapeutics has won FDA approval for a once-monthly cholesterol drug, Lerochol, that it says offers ease-of-use advantages over rivals.
Editor's Picks
Newsletters and Deep Dive
digital magazine